Overview

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

Status:
RECRUITING

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

This is a single-center exploratory clinical study to explore the efficacy and safety of Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator:

Huazhong University of Science and Technology

Treatments:

HMPL-013
Inulin
sintilimab